• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC.

作者信息

Gelsomino Francesco, Ambrosini Valentina, Melotti Barbara, Sperandi Francesca, Ardizzoni Andrea

机构信息

Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy.

Nuclear Medicine Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy.

出版信息

J Thorac Oncol. 2016 Aug;11(8):e99-e101. doi: 10.1016/j.jtho.2016.04.002. Epub 2016 Apr 12.

DOI:10.1016/j.jtho.2016.04.002
PMID:27079186
Abstract
摘要

相似文献

1
Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC.肿瘤学中的陷阱：在ALK重排的非小细胞肺癌中，色瑞替尼治疗期间成骨细胞反应模拟骨转移进展
J Thorac Oncol. 2016 Aug;11(8):e99-e101. doi: 10.1016/j.jtho.2016.04.002. Epub 2016 Apr 12.
2
A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.ALK 重排非小细胞肺癌患者长期鞘内给予色瑞替尼的脊髓内反应。
J Thorac Oncol. 2015 Jun;10(6):e44-5. doi: 10.1097/JTO.0000000000000501.
3
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌患者的色瑞替尼治疗及不良事件管理
Lung Cancer. 2017 Sep;111:51-58. doi: 10.1016/j.lungcan.2017.06.004. Epub 2017 Jun 9.
4
The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.色瑞替尼在ALK阳性非小细胞肺癌患者中的疗效。
Ther Adv Respir Dis. 2015 Oct;9(5):236-41. doi: 10.1177/1753465815597834. Epub 2015 Jul 30.
5
Clinical Efficacy of Alectinib in Patients with -Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.阿来替尼对色瑞替尼治疗失败的间变性淋巴瘤激酶重排非小细胞肺癌患者的临床疗效
Anticancer Res. 2017 Nov;37(11):6477-6480. doi: 10.21873/anticanres.12103.
6
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib.在对色瑞替尼耐药的ALK重排非小细胞肺癌患者中鉴定出一种新型ALK G1123S突变。
J Thorac Oncol. 2015 Jul;10(7):e55-7. doi: 10.1097/JTO.0000000000000509.
7
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.I1171错义突变（尤其是I1171N）是在接受阿来替尼治疗时病情进展且对色瑞替尼敏感的ALK阳性非小细胞肺癌患者中常见的耐药突变。
Lung Cancer. 2015 May;88(2):231-4. doi: 10.1016/j.lungcan.2015.02.005. Epub 2015 Feb 12.
8
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.阿来替尼（450mg/d 或 600mg/d 与食物同服或 750mg/d 空腹）治疗 ALK 阳性 NSCLC 患者的疗效和安全性：ASCEND-8 研究的主要疗效结果。
J Thorac Oncol. 2019 Jul;14(7):1255-1265. doi: 10.1016/j.jtho.2019.03.002. Epub 2019 Mar 7.
9
Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.色瑞替尼克服了一名ALK重排非小细胞肺癌患者对克唑替尼的原发性耐药。
Tumori. 2016 Nov 11;102(Suppl. 2):5782180D-F283-4AE9-A540-DC9D7B988B68. doi: 10.5301/tj.5000520.
10
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?在ALK重排的非小细胞肺癌中寻找新的万灵药：会是色瑞替尼吗？
Expert Opin Ther Targets. 2014 Sep;18(9):983-5. doi: 10.1517/14728222.2014.936383. Epub 2014 Jul 5.

引用本文的文献

1
[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time?[68Ga]镓-多他曲摄取于胰头/钩突部：随着时间推移它是否仍是持续存在的诊断陷阱？
Cancers (Basel). 2022 Jul 21;14(14):3541. doi: 10.3390/cancers14143541.
2
A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient: New osteoblastic bone lesions in a lung cancer patient may represent bone flare and should not be misdiagnosed as disease progression.意想不到的“ flare ”：一名肺癌患者中骨“ flare ”作为对酪氨酸激酶抑制剂治疗的反应：肺癌患者出现新的成骨性骨病变可能代表骨“ flare ”，不应误诊为疾病进展。
J Belg Soc Radiol. 2020 Apr 27;104(1):18. doi: 10.5334/jbsr.1907.
3
Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non-small cell lung cancer patients.
超声诊断联合靶向超声造影剂可提高超声对非小细胞肺癌患者的诊断敏感性。
Exp Ther Med. 2018 Aug;16(2):908-916. doi: 10.3892/etm.2018.6206. Epub 2018 May 23.